Clinical Trial Update: Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety and potential efficacy of treprostinil (Remodulin) to reduce ischemia-reperfusion injury and delayed graft f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function
• Ischemia-reperfusion Injury

Drugs mentioned

• Remodulin (treprostinil)

Snippet

Sponsor: Rhode Island Hospital | Conditions: Ischemia Reperfusion Injury, Delayed Graft Function | Phase 1, Phase 2 | Status: RECRUITING